Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there’s a catch.

Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.

Optimi Health announces the launch of six nootropic supplements derived from functional mushrooms.

Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and “repeated transcranial magnetic stmulation” treatments (rTMS).

COMPASS Pathways reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.

In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects on the intensity and quality of the psychedelic experience LONDON–(BUSINESS WIRE)–Small Pharma Inc., a neuroscience company focused on psychedelic-assisted therapies for mental health, is pleased…

Spiritual journey or clinical therapy? What does the future of psychedelic medicine look like?

Pharmather announces a method of use and composition of matter patent from the USPTO for its proprietary ketamine formulation, KETABET(TM).

During the quarter, Field Trip progressed its strategy of building the leading psychedelic therapy company through its Field Trip Health division and continued to invest in its lead drug development program.

Novamind announces a “clinical pilot” aimed at bringing ketamine-assisted therapy to treat the mental health disorders of frontline healthcare workers.